José Guzmán-Esquivel

Dr. José Guzmán-Esquivel

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
MMMartha A. Mendoza-Hernandez
Martha A. Mendoza-Hernandez
HGHannah P. Guzman-Solorzano
Hannah P. Guzman-Solorzano
KSKarla A. Sarmiento-Hernández
Karla A. Sarmiento-Hernández
IRIram Pablo Rodriguez-Sanchez
Iram Pablo Rodriguez-Sanchez
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Background: Risk factors for developing long COVID are not clearly established. The present study was designed to determine if any sign, symptom, or treatment of the acute phase, or personal characteristics of the patient, is associated with the development of long COVID. Methods: A cohort study was carried out, randomly selecting symptomatic COVID-19 patients and not vaccinated. The severity of the acute illness was assessed through the number of compatible COVID-19 symptoms, hospitalizations, and the symptom severity score using a 10-point visual analog scale. Results: After multivariate analysis, a severity score ≥8 (RR 2.0, 95%CI 1.1–3.5, p = 0.022), hospitalization (RR 2.1, 95%CI 1.0–4.4, p = 0.039), myalgia (RR 1.9, 95%CI 1.08–3.6, p = 0.027), tachycardia (RR 10.4, 95%CI 2.2–47.7, p = 0.003), and use of antibiotics (RR 2.0, 95%CI 1.1–3.5, p = 0.022), was positively associated with the risk of having long COVID. Higher levels of education (RR 0.6, 95%CI 0.4–0.9, p = 0.029) and type positive B blood group (B + AB, RR 0.44, 95%CI 0.2–0.9, p = 0.044) were protective factors. The most important population attributable fractions (PAFs) for long COVID were myalgia (37%), severity score ≥8 (31%), and use of antibiotics (27%). Conclusions: Further studies in diverse populations over time are needed to expand the knowledge that could lead us to prevent and/or treat long COVID.

10 June 2011 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
ASAlejandro D. Soriano-Hernández
Alejandro D. Soriano-Hernández
HGHector R. Galvan-Salazar
Hector R. Galvan-Salazar
DMDaniel A. Montes-Galindo
Daniel A. Montes-Galindo
ARAlejandrina Rodriguez-Hernandez
Alejandrina Rodriguez-Hernandez
RMRafael Martinez-Martinez
Rafael Martinez-Martinez
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso

10 July 2015 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
PDF file
ASAlejandro D. Soriano-Hernandez
Alejandro D. Soriano-Hernandez
DMDaniela G. Madrigal-Perez
Daniela G. Madrigal-Perez
HGHector R. Galvan-Salazar
Hector R. Galvan-Salazar
AAAlejandro Arreola-Cruz
Alejandro Arreola-Cruz
LBLorena Briseño-Gomez
Lorena Briseño-Gomez
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Background/Aims: Breast cancer is the most common gynecologic malignancy known worldwide. The consumption of certain foods may modify the risk for its development. Peanuts and other seeds have shown anticarcinogenic effects in vitro, but there are a few studies that evaluate the effect of their consumption on the development of breast cancer. The aim of the present study was to determine whether there is an association between the consumption of peanuts, walnuts, and almonds and the development of breast cancer. Methods: We analyzed 97 patients presenting with breast cancer and 104 control subjects that did not have the pathology (BIRADS 1-2). An analysis of the main clinical characteristics and lifelong seed consumption was carried out. The association between the consumption of these foods and the risk for breast cancer was estimated by odds ratios and 95% confidence intervals, controlling other risk factors, using the Mantel-Haenszel analysis. Results: The high consumption of peanuts, walnuts, or almonds significantly reduced the risk for breast cancer by 2-3 times. This protective effect was not found with low or moderate seed consumption when compared with null consumption. Conclusions: High consumption of peanuts, walnuts, and almonds appears to be a protective factor for the development of breast cancer.

1 June 2016 in International braz j urol
Verified
Journal Article
Open access
MMMiguel Maldonado-Avila
Miguel Maldonado-Avila
LGLeopoldo Garduño-Arteaga
Leopoldo Garduño-Arteaga
RJRene Jungfermann-Guzman
Rene Jungfermann-Guzman
HMHugo A. Manzanilla-Garcia
Hugo A. Manzanilla-Garcia
EREmmanuel Rosas-Nava
Emmanuel Rosas-Nava
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms. Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups: Group I: Tamsulosin 0.4 mg. Once per day(17 patients), Group II: Oxybutinin 5 mg. once per day (17 patients), Group III: Tamsulosin+ oxybutynin once per day (17 patients). All the groups received the drugs for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21. Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported. Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.

1 January 2018 in Archives of Medical Research
Verified
Journal Article
Closed access
Efrén Murillo-ZamoraEfrén Murillo-Zamora
Efrén Murillo-Zamora
OMOliver Mendoza-Cano
Oliver Mendoza-Cano
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
EHEnrique Higareda-Almaraz
Enrique Higareda-Almaraz
ALAGUSTIN LUGO-RADILLO
AGUSTIN LUGO-RADILLO

7 August 2015 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
ASAlejandro D. Soriano-Hernandez
Alejandro D. Soriano-Hernandez
DMDaniela Madrigal-Pérez
Daniela Madrigal-Pérez
HGHector R. Galvan-Salazar
Hector R. Galvan-Salazar
Margarita L. Martinez-FierroMargarita L. Martinez-Fierro
Margarita L. Martinez-Fierro
LVLaura Valdez
Laura Valdez
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Uterine cervical cancer (UCC) is one of the main causes of cancer‑associated mortality in women. Inflammation has been identified as an important component of this neoplasia; in this context, anti‑inflammatory drugs represent possible prophylactic and/or therapeutic alternatives that require further investigation. Anti‑inflammatory drugs are common and each one may exhibit a different antineoplastic effect. As a result, the present study investigated different anti‑inflammatory models of UCC in vitro and in vivo. Celecoxib, sulindac, nimesulide, dexamethasone, meclofenamic acid, flufenamic acid and mefenamic acid were tested in UCC HeLa, VIPA, INBL and SiHa cell lines. The cytotoxicity of the drugs was evaluated in vitro. Celecoxib, sulindac, nimesulide, mefenamic acid and flufenamic acid presented with slight to moderate toxicity (10‑40% of cell death corresponding to 100 µM) in certain cell lines, while meclofenamic acid exhibited significant cytotoxicity in all essayed cell lines (50‑90% of cell death corresponding to 100 µM). The meclofenamic acid was tested in murine models (immunodeficient and immunocompetent) of UCC, which manifested a significant reduction in tumor growth and increased mouse survival. It was demonstrated that of the evaluated anti‑inflammatory drugs, meclofenamic acid was the most cytotoxic, with a significant antitumor effect in murine models. Subsequent studies are necessary to evaluate the clinical utility of this drug.